JP2017533201A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533201A5
JP2017533201A5 JP2017521564A JP2017521564A JP2017533201A5 JP 2017533201 A5 JP2017533201 A5 JP 2017533201A5 JP 2017521564 A JP2017521564 A JP 2017521564A JP 2017521564 A JP2017521564 A JP 2017521564A JP 2017533201 A5 JP2017533201 A5 JP 2017533201A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
drug
subject
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533201A (ja
JP6675394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056383 external-priority patent/WO2016064817A1/en
Publication of JP2017533201A publication Critical patent/JP2017533201A/ja
Publication of JP2017533201A5 publication Critical patent/JP2017533201A5/ja
Application granted granted Critical
Publication of JP6675394B2 publication Critical patent/JP6675394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521564A 2014-10-22 2015-10-20 疾患及び障害の治療のためにインターロイキン−１０を使用する方法 Active JP6675394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067337P 2014-10-22 2014-10-22
US62/067,337 2014-10-22
PCT/US2015/056383 WO2016064817A1 (en) 2014-10-22 2015-10-20 Methods of using interleukin-10 for treating diseases and disorders

Publications (3)

Publication Number Publication Date
JP2017533201A JP2017533201A (ja) 2017-11-09
JP2017533201A5 true JP2017533201A5 (enExample) 2018-11-29
JP6675394B2 JP6675394B2 (ja) 2020-04-01

Family

ID=55761394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017521564A Active JP6675394B2 (ja) 2014-10-22 2015-10-20 疾患及び障害の治療のためにインターロイキン−１０を使用する方法

Country Status (11)

Country Link
US (2) US10143726B2 (enExample)
EP (1) EP3209320B1 (enExample)
JP (1) JP6675394B2 (enExample)
KR (1) KR20170084033A (enExample)
CN (1) CN107106655A (enExample)
AU (1) AU2015336101A1 (enExample)
CA (1) CA2963995A1 (enExample)
ES (1) ES2941234T3 (enExample)
MX (1) MX2017004983A (enExample)
WO (1) WO2016064817A1 (enExample)
ZA (1) ZA201702214B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2616045T3 (enExample) 2010-09-15 2018-03-24
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
KR20230154480A (ko) 2014-05-07 2023-11-08 어플라이드 몰레큘라 트랜스포트 인크. 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
EP3402512A4 (en) 2016-01-11 2019-09-25 Armo Biosciences, Inc. INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Colics-derivative carriers for oral administration of heterologous cargo
TW202031678A (zh) 2018-11-07 2020-09-01 美商應用分子運輸公司 用於胞移作用及相關方法之遞送構築體
US20220105190A1 (en) * 2019-02-04 2022-04-07 Lipoxen Technologies Limited Methods of using glycopolysialylated therapeutic proteins
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202840A (en) 1985-06-10 1986-04-08 Jonathan R. Kleinsasser Combination wet and dry feeder for animals
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5032396A (en) 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5156301A (en) 1990-12-17 1992-10-20 Imi Cornelius Inc. Constant ratio post-mix beverage dispensing valve
DK0567586T3 (da) 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
HU218598B (hu) 1991-01-16 2000-10-28 Schering Corp. Eljárás interleukin-10-et tartalmazó, tumorok kezelésére szolgáló gyógyszerkészítmények előállítására
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994017773A2 (en) 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
WO1994022473A1 (en) 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
SK8396A3 (en) 1993-07-26 1997-03-05 Schering Corp Antagonists and agonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
EP0740552A1 (en) 1994-01-20 1996-11-06 Schering Corporation Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5759859A (en) 1996-07-15 1998-06-02 United States Of America As Represented By The Secretary Of The Army Sensor and method for detecting trace underground energetic materials
US5945097A (en) 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
EP1140142A2 (en) 1998-12-22 2001-10-10 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
AU5827000A (en) 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
AU2002307497A1 (en) 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
DK1565183T3 (da) 2002-11-29 2008-12-01 Maria Grazia Roncarolo Rapamycin og IL-10 til behandling af autoimmune sygdomme
WO2004056850A2 (en) 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP5466350B2 (ja) 2003-03-03 2014-04-09 ダイアックス、コープ ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
EP2261244A3 (en) 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005033307A1 (ja) 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
DE602004025509D1 (de) 2003-11-28 2010-03-25 Univ Sydney Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
WO2006061219A2 (en) 2004-12-09 2006-06-15 Merck Patent Gmbh Il-7 variants with reduced immunogenicity
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP4992025B2 (ja) 2005-05-31 2012-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 変異体ｉｌ−１０
US8945857B2 (en) 2005-07-01 2015-02-03 John Schrader Methods of isolating cells and generating monoclonal antibodies
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
JP5364375B2 (ja) 2005-10-04 2013-12-11 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２９の生産および精製の方法
US7939056B2 (en) 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
WO2008041953A2 (en) 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
EP2949671A1 (en) 2009-10-12 2015-12-02 Pfizer Inc Cancer treatment
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
EP2933262B1 (en) 2010-07-09 2018-05-02 Affibody AB Polypeptides
US8759617B2 (en) 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
CA2813849C (en) * 2010-11-05 2021-06-15 Novartis Ag Secukinumab for use in the treatment of ankylosing spondylitis
SG10201602253SA (en) 2011-03-23 2016-05-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
WO2014172392A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
HK1215595A1 (zh) 2013-04-24 2016-09-02 Armo Biosciences, Inc. 白細胞介素-10藥物組合物和使用方法
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015108785A1 (en) 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3237441A4 (en) 2014-12-23 2018-06-06 Armo Biosciences, Inc. Methods of improving yield in recombinant protein production
KR20170125839A (ko) 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Ｉｌ-7 부분 및 중합체의 접합체
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10

Similar Documents

Publication Publication Date Title
JP2017533201A5 (enExample)
RU2015149387A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2020203889A (ja) 抗体製剤
JP2016074740A5 (enExample)
JP2016514132A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2015520188A5 (enExample)
JP2019519519A5 (enExample)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2016530284A5 (enExample)
JP2019535651A5 (enExample)
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2017503014A5 (enExample)
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
EA200802350A3 (ru) Система доставки лекарств
RU2016114098A (ru) Новое производное аналога инсулина
ES2908141T3 (es) Formulaciones y dosis de cannabinoides
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2018530525A5 (enExample)
JP2013520447A5 (enExample)
JP2018530612A5 (enExample)
JP2019501925A5 (enExample)
JP2009538916A5 (enExample)